Completed PHASE1 INTERVENTIONAL 2-arm NCT02834442

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects

A Randomised, Double Blind, Placebo Controlled Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of MT-7117 in Healthy Subjects

Sponsor: Tanabe Pharma Corporation

Conditions Healthy

Interventions MT-7117 Placebo

Updated 8 times since 2017 Last updated: Jul 24, 2017 Started: Jul 31, 2016 Primary completion: Jun 30, 2017 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Tanabe Pharma Corporation leads this study, which shows 8 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE1
Sep 2024 — Jan 2026 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Aug 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jun 2017 — Aug 2017 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jan 2017 — Jun 2017 [monthly]

Recruiting PHASE1

First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tanabe Pharma Corporation

Data source: Tanabe Pharma Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• United Kingdom, United Kingdom